We are live on ! Find out more
ELEV

Elevation Oncology
ELEV

Delisted

ELEV was delisted on the 22nd of July, 2025.

Back to rankings

32 hedge funds and large institutions have $13.9M invested in Elevation Oncology in 2023 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

14% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 7

5.24% less ownership

Funds ownership: 66.18% → 60.94% (-5.2%)

22% less funds holding

Funds holding: 41 → 32 (-9)

25% less capital invested

Capital invested by funds: $18.6M → $13.9M (-$4.7M)

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

90% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 10

Holders
32
Holders Change
-9
Holders Change %
-21.95%
% of All Funds
0.47%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.03%
New
1
Increased
8
Reduced
7
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$234K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$53.7K
3
BlackRock
BlackRock
New York
+$22.9K
4
Two Sigma Advisers
Two Sigma Advisers
New York
+$13.7K
5
UBS Group
UBS Group
Switzerland
+$2.07K

Top Sellers

Rank Fund Capital Flow
1
ECM
ExodusPoint Capital Management
New York
-$662K
2
AC
Armistice Capital
New York
-$497K
3
TCM
Tang Capital Management
California
-$176K
4
Citadel Advisors
Citadel Advisors
Florida
-$132K
5
Walleye Capital
Walleye Capital
New York
-$98.7K
Name Holding Trade Value Shares
Change 		Change in
Stake
TCM
1
Tang Capital Management
California
$1.97M -$176K -332,400 -8%
Millennium Management
2
Millennium Management
New York
$1.61M -$22.2K -41,935 -1%
VP
3
venBio Partners
California
$1.56M – – –
ACM
4
Aisling Capital Management
New York
$1.52M – – –
QUSVM
5
Qiming U.S. Ventures Management
Washington
$1.27M – – –
BI
6
BVF Inc
California
$1.24M – – –
O
7
OrbiMed
New York
$806K – – –
IC
8
Ikarian Capital
Texas
$629K – – –
Vanguard Group
9
Vanguard Group
Pennsylvania
$629K +$53.7K +101,441 +9%
SFM
10
Sphera Funds Management
Israel
$483K – – –
Citadel Advisors
11
Citadel Advisors
Florida
$318K -$132K -248,718 -30%
Hudson Bay Capital Management
12
Hudson Bay Capital Management
Connecticut
$293K – – –
VCIM
13
Velan Capital Investment Management
Georgia
$267K – – –
DCM
14
DAFNA Capital Management
California
$242K – – –
Renaissance Technologies
15
Renaissance Technologies
New York
$237K +$234K +441,490 New
Two Sigma Investments
16
Two Sigma Investments
New York
$196K -$39K -73,696 -17%
BFM
17
Boothbay Fund Management
New York
$138K – – –
Geode Capital Management
18
Geode Capital Management
Massachusetts
$124K – – –
Bank of America
19
Bank of America
North Carolina
$83K +$11 +21 +0%
UBS Group
20
UBS Group
Switzerland
$69K +$2.07K +3,904 +3%
Two Sigma Advisers
21
Two Sigma Advisers
New York
$55.1K +$13.7K +25,900 +34%
BlackRock
22
BlackRock
New York
$43.3K +$22.9K +43,249 +116%
AC
23
Annandale Capital
Texas
$27K – – –
Northern Trust
24
Northern Trust
Illinois
$23.9K – – –
State Street
25
State Street
Massachusetts
$22.6K – – –
1
2

ELEV Hedge Fund Activity: Q4 2023 in Review

32 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Elevation Oncology (ELEV) for Q4 2023, worth a combined $13.9M — down 25% from $18.6M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of ELEV and 1 opened new positions — a net loss of 9 holders — while 7 trimmed existing stakes and 8 added.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $234K. The largest seller was ExodusPoint Capital Management, exiting entirely with an estimated $662K sold.

  • 32 institutional investors held Elevation Oncology (ELEV) as of Q4 2023, down from 41 in Q3 2023.
  • Funds reported $13.9M of Elevation Oncology stock for Q4 2023, down 25% quarter-over-quarter.
  • 1 fund opened new Elevation Oncology positions in Q4 2023 and 10 closed out, a net change of -9 holders.
  • The largest Elevation Oncology buyer in Q4 2023 was Renaissance Technologies, an estimated $234K added.
  • The largest Elevation Oncology seller in Q4 2023 was ExodusPoint Capital Management, an estimated $662K sold.

Based on aggregated 13F filings for Q4 2023.